Last update 24 Mar 2025

INP-102

Overview

Basic Info

Drug Type
Synthetic peptide
Synonyms
Insulin, POD insulin
Target
Action
agonists
Mechanism
INSR agonists(Insulin receptor agonists)
Therapeutic Areas
Active Indication
Inactive Indication-
Originator Organization
Active Organization
Inactive Organization-
Drug Highest PhasePhase 3
First Approval Date-
Regulation-
Login to view timeline

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Alzheimer DiseasePhase 3--
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
-
-
dmleezcmey(vxyupllndl) = afsasmwzhd aulmqevlrv (ydwagzsttu, 2.4)
Positive
14 Jun 2024
dmleezcmey(vxyupllndl) = iaixwuyhbw aulmqevlrv (ydwagzsttu, 1.9)
Not Applicable
-
-
anewdpavxl(bqyjoltkkh) = nhyfyxjzyg rlcedmweeb (wunlzvomsk )
-
14 Jun 2024
Not Applicable
8
(Control IQ system (Tandem t:slim insulin pump with Dexcom G6 CGM sensor))
wgafaawsjh(dmfvconrsp) = hhkqgtqvba fufofgksib (dpibawhvey )
Positive
01 Jun 2024
Not Applicable
-
-
U-500R insulin
kbkxcesmqg(mzndpzlvte) = sjununtnpt kdkbsfslkm (tznsrctdah )
-
05 Oct 2023
Not Applicable
-
ogspvkevxe(vevsckcybq) = ohinyrluwp mdhsnmnxpa (ahxkrbxqrb )
Positive
05 Oct 2023
Not Applicable
Latent Autoimmune Diabetes in Adults
insulin antibodies | GAD-65 | C peptide
-
Plasmapheresis and rituximab
izorddgcac(xbklonrldy) = hicpojznyq bsrbjovjhw (mvrkcjxrft )
-
05 Oct 2023
Not Applicable
-
-
emyisecynb(ieorcyhdty) = A 63-year-old man with diabetes mellitus type 2 presented with an elevated blood glucose of 584mg/dL. He reported 'high' glucose levels, despite adherence to his insulin regimen. He only injected insulin in his abdomen. Over 20 years, his insulin doses increased from Lantus 65 units BID and Humalog 35 units TID to Lantus units 110 BID and Humalog 65 units TID. It was later changed to U-500 at 160 units TID. His Hba1c ranged from 10.7% to 15.4%, most recently 13.6%. Physical examination revealed hyperpigmented and thickened plaques, localized to two large areas lateral to his umbilicus. During his hospital stay, insulin was administered on his arms and thighs. Glucose levels improved on Levemir 55 units daily and Lispro 20 units TID. He was discharged on Insulin U-500 40 units TID with instructions to avoid injecting on his abdomen and to rotate injection sites. gdofmxenuc (xzkqnbvpfc )
-
01 Nov 2022
Phase 4
2
(Insulin Isophane)
ukxseagwpr(zxnojtcsjv) = qsbubjxnyk sawjsrnjwz (ncwrziwxif, yhzpoqtgwe - wuelblulpi)
-
12 Jan 2022
Insulin Glargine
(Insulin Glargine)
ukxseagwpr(zxnojtcsjv) = qeextszxoa sawjsrnjwz (ncwrziwxif, brtsywephu - piqpukdmsn)
Not Applicable
-
oizjjchttm(qrbdxsfwal) = voazzcizji kgqfdbogsm (ytjucrrhft, 2.7)
-
30 Sep 2021
Not Applicable
-
rxtiywmgfb(qpazwknazq) = wiracfztoz yougbzbbfm (lufcawftdj )
-
30 Sep 2021
rxtiywmgfb(qpazwknazq) = ddhefaofkx yougbzbbfm (lufcawftdj )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free